Patients with cancer account for >20 % of all patients newly diagnosed with venous thromboembolism (VTE), which remains a leading cause of morbidity and mortality in this patient population [1]. Significant progress has been made in the management of cancer-associated VTE, particularly with the introduction of direct oral anticoagulants (DOACs), which have proven to be effective, safe, and more convenient than low molecular weight heparin. Hence, DOACs have become widely utilized in the management of patients with cancer-associated VTE, supported by evidence from pivotal randomized trials such as the Caravaggio trial [2].
